J Korean Neurosurg Soc.
1998 Jul;27(7):967-974.
The Relationship between Clinical Features and Changes of Proliferative Activity Analysed by Ki-67 in Recurrent Astrocytic Tumors
- Affiliations
-
- 1Department of Neurosurgery, Chonnam University Hospital & Medical School, Kwangju, Korea.
- 2Department of Pathology, Chonnam University Hospital & Medical School, Kwangju, Korea.
- 3Chonnam National University Research Institute of Medical Sciences, Chonnam University Hospital & Medical School, Kwangju, Korea.
Abstract
- The relationship between the proliferative activity and clinical features in 21 cases of recurrent astrocytic tumors were studied. The proliferative activity of tumor cell was analysed by Ki-67 labelling index using immunohistochemistry for MIB-1 antibody. Positive relationships were noted on clinical features, such as mean ages, time interval between primary and secondary operation, postoperative survival, and histopathologic grade with Ki-67 labelling indices in the primary tumors. Unlike to these, clinicopathologic characteristrics were not positively correlated in secondary recurrent tumors. It is thus suggested that Ki-67 labelling indices would be valuable in the estimations of clinical prognosis and histopathologic grades in the primary astrocytic tumors but might not be in the recurrent astrocytic tumors due to change of biologic features of tumor cell after radiotherapy and/or chemotherapy.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Bcl-2 and Bax Expression and Ki-67 Proliferative Index in Astrocytic Tumors: in Relation to Prognosis
- Comparative Evaluation of p53-protein Expression and Proliferating Indices in Astrocytic Tumors
- p53 Expression and Ki-67 Labeling Index in Brain Tumor with Special Reference to Tumor and Histologic Grade
- Analysis of Proliferative Potentials in Meningiomas by Ki-67, Proliferating Cell Nuclear Antigen, and Flow Cytometry
- Ki 67 Expression and Its Correlation with the Proliferative Index Measured by Flow Cytometry in Breast Carcinoma
